Objective. The objective of this study was to determine predictors of 1-year remission in early RA (ERA) using baseline and 3-month data.
Introduction
RA is a chronic, inflammatory disease with long-term outcomes that are difficult to predict. The course of the disease ranges from drug-free remission to joint destruction and disability [1] . Better and earlier treatment with DMARDs and/or biologics has been shown to improve symptoms, radiological outcomes and associated morbidity. This is particularly true in early RA (ERA) before irreversible damage has occurred [2] . The adoption of a tight-control strategy, which involves aiming for as low disease activity as possible, has also improved patient outcomes compared with routine care [3] . There also may be a window of opportunity during which RA is more responsive to treatment [4] . Accurately predicting future disease activity would be helpful in ERA so appropriate treatment can commence as early as possible.
A qualitative, physician global assessment (PGA) of disease activity is used by many rheumatologists in their clinical decision making [5] . The PGA, when used as a 010 continuous visual analogue scale (VAS), has demonstrated excellent testretest reliability in RA patients [6] . In addition, it has been shown to be more accurate and sensitive to changes in arthritis activity than other measures such as pain scores, disability indices and laboratory measures [7] . Studies have demonstrated that following RA disease activity with the 28-joint DAS (DAS28), Clinical Disease Activity Index (CDAI) or Simple Disease Activity Index (SDAI) leads to improved patient outcomes [8] . The HAQ has been shown to reflect activity and damage and has also been used in following RA patients in routine care [9] . In daily practice, however, a low correlation exists between measurements such as the DAS28 and PGA, which may be due to the presence of patient co-morbidities that affect pain such as OA and mechanical back pain [5, 10] . Multiple studies have demonstrated that the PGA is an important component of a physician's decision to increase treatment [11, 12] . In a recent study on patients from a large prospective cohort, the Canadian Early Arthritis Cohort (CATCH), the PGA was shown to be even more important than the DAS in deciding to increase treatment [11] . In a previous study by Wessels et al. [13] , the PGA at baseline was not significantly correlated with future patient disease activity status in a multivariate analysis. This is not unexpected, however, given that at baseline we do not know whether patients will respond well to treatment nor can we predict who will be adherent and who will have side effects. This is corroborated by other studies, which have found that disease activity after 36 months of follow-up appears to be a better predictor than baseline characteristics [14] .
There are many therapeutic strategies for ERA treatment; however, it remains uncertain whether every patient will need the same intensity of traditional and biologic DMARDs. An easy tool to predict disease status at 1 year would allow for more rational prescribing. Randomized controlled trials (RCTs) have demonstrated that the response to treatment early, such as 3 months, can predict later responders [15, 16] . In usual care, the same may or may not be true.
The purpose of this study was to determine whether future disease activity can be predicted in ERA using the PGA and comparing it with other parameters. It was hypothesized that patients with a higher PGA at 3 months will be associated with poorer outcomes at 1 year. The ability to know as early as possible who will have a good prognosis and be in a low disease state vs who won't can lead to more appropriate treatment choices in ERA.
To address this question we studied PGA results at 3 months after the first visit for patients with early inflammatory arthritis (EIA) enrolled in the CATCH cohort to determine the strength of the prediction for the presence of remission at 12 months.
Methods

Subjects
Data were collected from 1844 patients enrolled in the CATCH study. CATCH is an observational, prospective, real-world cohort of patients with EIA recruited at 15 sites since July 2007, with the majority from Ontario and Quebec. All patients signed informed consent and the CATCH project was approved at all sites by the respective institutional review boards. Inclusion criteria were age >16 years, between 6 weeks and 12 months of persistent synovitis at the time of entry, and 52 swollen joints or 1 swollen metacarpophalangeal or proximal interphalangeal joint and 51 of the following were required: positive RF, positive anti-CCP, morning stiffness >45 min, response to NSAIDs or a painful metatarsophalangeal squeeze test. At each visit a case report form was completed that collects global assessments, joint counts and inflammatory markers; a calculation of composite scores was not mandated. Patients were evaluated at baseline and at subsequent visits (every 3 months in the first year and every 6 months thereafter) according to a standard protocol. Treatment was left to the discretion of the treating physician and included monotherapy or combinations of DMARD therapy and biologics, as well as the option of oral, i.m. or IA glucocorticoids [17] .
Statistical analysis
Patients who had completed study visits at 0 (baseline), 3 and 12 months, and who were not in remission at baseline, were included in this study. The relationship between variables at baseline and 3 months with outcomes at 12 months was examined. Four remission definitions were evaluated: (i) SDAI score 43.3; (ii) CDAI score 42.8; (iii) DAS28 <2.6; (iv) Boolean-based ACR/ European League Against Rheumatism (EULAR) clinical trial definition requiring a tender joint count (TJC) 41, swollen joint count (SJC) 41, patient global assessment (PtGA) of disease 41 on a 010 cm scale and CRP 41 mg/dl using 28 TJC/28 SJC [18] . Factors examined at baseline and 3 months included in the univariate analyses were age, gender, TJC, SJC, ESR, CRP, PGA, PtGA, pain and HAQ. Co-morbidity, income, education, RF and anti-CCP statuses were only examined at baseline, while medication (use of a DMARD or not) was examined at month 3. The relationship between the remission outcomes and predictor variables was calculated using point-biserial correlations for continuous variables and chi-square analysis for dichotomous variables. Point biserial correlations were used to explore whether 3-month measures were more strongly related to outcome at 1 year than baseline measures.
Multivariate analyses with forward stepwise logistic regression were performed to determine the combination of factors that best predicted remission at 12 months and the results were expressed as odds ratio (OR) with 95% CI. Sensitivity and specificity data from the logistic regression classification tables were also reported, along with the associated area under the curve from the receiver www.rheumatology.oxfordjournals.org 483 MD global at 3 months predicts remission in ERA at 12 months operator characteristic (ROC). Univariate analyses were included in a regression model when P < 0.1, whereas a two-tailed P < 0.05 was considered statistically significant in the regression model. Only patients with complete data at 12 months were included in the regression model. For variables with measurements at baseline and 3 months, only the 3-month measurements were included in the model. In addition, interactions between age and PGA as well as gender and PGA were studied. Correlation coefficients and variance inflation factor (VIF) diagnostics were used to exclude collinearity, and the HosmerLemeshow test was used to assess goodness of fit. Statistical analyses were performed using SPSS software, version 19.
Results
A total of 1150 patients in the cohort recorded visits at all three time points and up to 854 had response data. The full dataset for the variables of interest at 12 months was available in 502 patients for SDAI outcome, 562 for CDAI outcome, 527 for DAS28 outcome and 516 for Booleanbased outcome (Fig. 1) . The logistic regression analyses were limited to these patients. The excluded group for CDAI remission had fewer people with low income (11% compared with 16% in those who were analysable).
The excluded groups for SDAI and CDAI remission were also older by an average of 2 years. Overall, the mean age was 53.5 (S.D. 14.6) years; 73.2% were female. At baseline, 53% of patients were positive for anti-CCP and 61% were positive for RF; 45.6% of patients did not have postsecondary education and 13.9% earned <$20 000 per year; 87.5% had at least one comorbidity at baseline and most received DMARDs. Remission rates for Boolean and DAS <2.6 definitions ranged from 9.6% to 29.6% at month 3 and 20.0% to 44.9% at month 12, respectively. Mean values of the other variables are shown in Table 1 . The factors at baseline associated with all four remission outcomes at 12 months in univariate analyses (P < 0.1) were age, gender, low income, any co-morbidity, TJC, PtGA, HAQ and pain. ESR at baseline was associated with DAS28 remission only and education was associated with DAS28, CDAI and SDAI remission but not Boolean-based remission. The factors at 3 months associated with all four remission outcomes were TJC, SJC, PGA, PtGA, HAQ, pain, ESR and CRP. Correlations between these variables and the outcomes are shown in Table 2 . Measurements at 3 months were found to be more strongly correlated with outcomes at 12 months compared with baseline variables. Overall, the strength of the correlations between the predictor variables and remission outcomes was weak to moderate. 
Discussion
Treating ERA patients early and aggressively with targeted outcomes has been shown to improve outcomes in multiple studies [8] . To date, however, there is no consensus among rheumatologists for which measure to use in clinical practice. A previous study on the CATCH cohort demonstrated that PGA was most strongly associated with an increase in therapy in ERA patients [11] . To follow up on that study, our goal was to determine if, in the first 3 months of ERA treatment, the PGA or other 485 MD global at 3 months predicts remission in ERA at 12 months measures was strongly predictive of outcome at 1 year as measured by different remission criterion. Remission rates in ERA have been known to vary substantially across different observational studies, in part due to different definitions. In particular, the Boolean-based ACR/EULAR variant is much more stringent than other definitions and gives a lower remission rate, whereas the DAS28 definitions lead to a higher rate but lower sustained remission rate [18] . By including multiple remission outcomes in our study, we were able to test the consistency of variables to predict outcome at 1 year of treatment. Some of our findings are comparable to those of other studies. Older age and female gender are known to be associated with worse outcomes [3, 14, 19, 20] . In our study we found age to be most significant in predicting DAS28 remission outcome. However, the OR for age is fairly close to 1 (0.975). The OR for female gender was larger, but the wider CI also leads to difficulty in interpreting clinical significance. For HAQ scores, a higher score was associated with poorer treatment response in studies for ERA patients but not established arthritis patients [13, 14, 21] . Similarly, HAQ scores were found in our study to be significantly associated with DAS28 and SDAI definitions, albeit with a higher standard error than other variables. In general, it is agreed that variables taken at baseline are less predictive than those measured at a later time point [22] . Our study results for PGA further confirmed this finding; variables measured at 3 months had a higher correlation than those measured at baseline in the univariate analyses. It is intuitive that not just the level of baseline disease activity, but early response to treatment would be most predictive of later disease state. Whereas Wessels et al. [13] found that baseline PGA and pain did not predict remission in multivariate analyses, in our study pain and PGA measured at 3 months were consistently associated with outcome at 12 months. In particular, it is worth noting that the PGA was the most statistically significant independent variable in the model for SDAI and CDAI definitions, and was second to only ESR for the DAS28 remission definition. Given the importance of ESR in calculating DAS28 scores, these findings are not surprising [18] .
RCTs for biologics in RA have looked at the state a patient is in, such as the DAS28 score and the change in DAS28, and related this to the chance of remission at 12 months [15, 16, 22] . These studies demonstrated that a low DAS28 score at week 12 predicts remission at 1 year. The PGA was not studied in these trials, however, as it is not part of the DAS28 score. In addition, the present study differs from these RCTs in several other ways. Our study involved patients with ERA rather than established RA and our data are from a heterogeneous population of patients in usual care as opposed to a specific treatment arm of a placebo-controlled clinical trial. Furthermore, we did study multiple patient outcomes (pain, global assessment of disease activity and HAQ), but did not study fatigue. Our study contained several remission outcomes [18] . Another way of studying those with a good outcome at 1 year would be to look at the kinetics of response (how rapid and how large a change in the DAS28). Some studies have done this in established RA, and indeed rapid and large responders do better in the future. In some tight control trials, DAS28 scores have been used to monitor patients and to increase treatment if a low DAS target has not been reached [6] . Pyne et al. [11] have shown (using data from the CATCH cohort) that the DAS28 has a relatively small impact on a physician's decision to increase treatment in Canada. This finding is also corroborated by other studies in the USA, which found a similar lack of reliance on DAS28 scoring [5] . Instead, it was found that many physicians incorporate the PGA results in their decision making [11] . Our study shows that in the same group of patients, the PGA measured at 3 months is also significantly associated with patient outcome and suggests that the PGA may be useful as a monitoring tool for tight-control interventions and predicting who may or may not achieve remission at 12 months using 3 months data. The use of the PGA is expected to offer several benefits compared with DAS scoring. For example, the PGA is less likely to be affected by the presence of patient comorbidities that may inflate the PtGA component of the DAS. In addition, as a systematic assessment, the PGA allows the physician to differentiate between patients with a similar number of affected joints but whose severity may differ. Further study is warranted to explore and possibly expand the role of PGA in treating ERA.
Our study contained a more than adequate sample size for the number of variables studied. There are few missing data with the exception of anti-CCP status, which was not included as a factor in multivariate analysis, as it is missing in 30% of Canadian patients since this test is not reimbursed in all regions of the country or not always ordered as part of routine care. However, given that this is an inception cohort from multiple sites throughout Canada, data from CATCH cohort is more likely to reflect clinical practice and results should be generalizable to typical patients with new-onset RA who are managed with usual care.
There are some limitations. We studied only remission at 12 months, whereas sustained remission may be an important endpoint, but the proportion of patients in remission at 1 year is an important endpoint of most ERA cohort studies and relevant to patients, as there may be a window of opportunity early on to achieve remission and many DMARD changes are made within the first year of treatment. We performed several analyses, but had multiple remission definitions that showed fairly consistent results. In addition, although the same question was asked of physicians for completion of the PGA, it is possible that different physicians may have different interpretations of the question. This, however, does not alter the interpretation of the results of this study. Future studies could TABLE 3 Multivariate analysis of predictors of remission at 12 months using data from baseline and 3 months 
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. Remission at 1 year in early RA is predicted most strongly by the 3-month physician global assessment. . The DAS at baseline and 3 months does not strongly predict remission at 1 year in early RA.
